Kali Extracts To Release Report On Cannabis Extracts For COPD

Kali Extracts Inc. (OTCMKTS:KALY) has announced that they are planning to give a presentation preview on the impact of cannabis on COPD, or chronic obstructive pulmonary disease. They have scheduled the presentation for tomorrow, the 5th of February where Fred Ferril Kali’s CEO and Professor Jeffry Osbourn of Kentucky University will publish the preliminary results online.

Story continues below

Chronic Obstructive Pulmonary Disease

Kali has already released previous results of the vitro genomic study. The study evaluated the effect of their pharmaceutical grade cannabis extracts and a combination of other therapies in the management of COPD patients.

In addition to the previous in vitro genomics study, the company has equally finalized a long-term pilot study on the use of pharmaceutical cannabis extracts in the treatment of COPD in primates. The preliminary review of the results that the company has scheduled for February 5th will provide further insight into the ongoing primate study as the company waits to give a comprehensive report on the study by March.

Kali product portfolio

Kali-Extracts focuses on health and wellness, and generates revenue from a cannabis extraction platform that they have patented.

The company is utilizing their patented cannabis extraction technology to develop and process various wellness and health products internally as well as through external partnerships. Also, the company has been employing the patented cannabis extraction technology in developing pharmaceutical products in house as well as through collaborations with other companies.

Their extraction process is licensed to CBD-infused beverages production company Puration, Inc. (OTCMKTS:PURA). Puration’s twelve-month sales have been trailing at approximately $1 million, and their sales of the EVERx CBD sports water is growing in popularity.

Currently, Kali is working with Puration on the development of a new 25mg CBD formulation that will be used by Puration to produce new CBD-infused water. The two companies have signed a $1 million agreement to jointly produce customized CBD infused drink for Generex Biotechnology Corporation (OTCMKTS:GNBT). The new GNBT drink will be available on the shelves soon.

An ad to help with our costs